FORTRESS BIOTECH INC (FBIO)
US34960Q3074 - Common Stock
| 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 80.93M | 178.30M | 305.70M | 233.40M | 136.90M | |||
| Marketable Securities | N/A | N/A | N/A | N/A | 0.00 | |||
| Receivables | 15.39M | 28.30M | 23.80M | 24.70M | 14.40M | |||
| Inventories | 10.21M | 14.20M | 9.90M | 1.40M | 900.00K | |||
| Other Current Assets | 10.50M | 9.70M | 7.10M | 6.70M | 4.10M | |||
| Total Current Assets | 117.02M | 230.40M | 346.50M | 266.20M | 156.30M | |||
| Non-Current Assets | ||||||||
| PPE Net | 23.50M | 33.00M | 34.10M | 32.40M | 33.90M | |||
| Investments And Advances | N/A | N/A | 0.00 | 17.60M | 11.10M | |||
| Goodwill | N/A | N/A | N/A | N/A | N/A | |||
| Intangibles | 20.29M | 27.20M | 12.60M | 14.60M | 7.40M | |||
| Other Non-Current Assets | 6.72M | 3.70M | 3.40M | 2.70M | 17.70M | |||
| Total Non-Current Assets | 50.50M | 63.90M | 50.00M | 67.20M | 70.10M | |||
| TOTAL ASSETS | 167.53M | 294.30M | 396.50M | 333.40M | 226.40M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 3.00M | 7.20M | 4.50M | 4.50M | 7.20M | |||
| Accrued Expenses | 23.06M | 22.80M | 25.30M | 18.60M | 15.50M | |||
| Accounts Payable | 53.03M | 77.10M | 67.40M | 28.50M | 22.90M | |||
| Other Current Liabilities | 5.82M | 20.60M | 3.80M | 100.00K | 0.00 | |||
| Total Current Liabilities | 84.91M | 127.70M | 101.00M | 51.80M | 45.60M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 60.86M | 93.10M | 46.60M | 59.80M | 82.40M | |||
| Other Non-Current Liabilities | 20.18M | 23.40M | 23.00M | 24.80M | 25.80M | |||
| Total Non-Current Liabilities | 60.07M | 124.90M | 186.80M | 181.30M | 154.60M | |||
| TOTAL LIABILITIES | 144.98M | 252.60M | 287.80M | 233.10M | 200.20M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -694.87M | -634.20M | -547.50M | -482.80M | -436.20M | |||
| Additional Paid In Capital | 717.40M | 675.80M | 656.00M | 583.00M | 461.90M | |||
| Minority Interest | 72.56M | 135.64M | 217.32M | 153.16M | 108.00M | |||
| Common Shares | 18.00K | 100.00K | 100.00K | 100.00K | 600.00K | |||
| Shares Outstanding | 15.09M | 7.40M | 6.80M | 6.30M | 4.90M | |||
| Tangible Book Value per Share | 0.15 | 1.96 | 14.13 | 13.60 | 3.84 | |||
| Total Shareholders' Equity | 22.54M | 41.70M | 108.70M | 100.30M | 26.20M | |||
| TOTAL LIABILITIES AND EQUITY | 167.53M | 294.30M | 396.50M | 333.40M | 226.40M | |||
| Statistics | ||||||||
| Debt/Equity | 2.70 | 2.23 | 0.43 | 0.60 | 3.15 | |||
| Current Ratio | 1.38 | 1.80 | 3.43 | 5.14 | 3.43 | |||
| Return On Assets (ROA) | -40.99% | -29.42% | -16.32% | -13.96% | -17.65% | |||
| Return On Equity (ROE) | -304.60% | -207.63% | -59.52% | -46.39% | -152.52% | |||
All data in USD